Partial
Partially Aligned
Patient Risk:
Low
Summary
The response accurately reflects label information about administration with food, grapefruit juice, CYP3A4-related interactions, myopathy, rhabdomyolysis, and hepatic precautions. However, several central yogurt-, calcium-, and protein-specific conclusions are not addressed by the supplied label, and the dark-urine statement is also absent from the label. The response appropriately identifies these limitations but still presents some unsupported external-evidence conclusions.
Category Scores
Accurate Statements
Certain foods and drinks can affect atorvastatin absorption or metabolism.
The label states that food affects absorption, grapefruit juice can increase atorvastatin concentrations through CYP3A4 inhibition, and CYP3A4 inducers can reduce atorvastatin concentrations.
Grapefruit and grapefruit juice can raise blood levels of some statins by affecting drug metabolism.
The label specifically states that grapefruit juice can increase plasma concentrations of atorvastatin by inhibiting CYP3A4.
Increased statin blood levels can increase the risk of side effects.
The label links increased atorvastatin exposure from interacting drugs with increased risk of myopathy and rhabdomyolysis.
Certain antibiotics, antifungals, HIV medications, and other drugs that affect liver enzymes can interact with atorvastatin.
The label identifies clarithromycin, itraconazole, HIV protease inhibitor combinations, erythromycin, and other interacting agents as affecting atorvastatin exposure or muscle toxicity risk.
New muscle pain or weakness can be a statin adverse effect.
The label describes myopathy as muscle aches or weakness with elevated CPK and instructs patients to promptly report unexplained muscle pain, tenderness, or weakness.
The label advises caution in patients consuming substantial quantities of alcohol.
Section 5.2 states that LIPITOR should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease.
The label's major safety issues include myopathy/rhabdomyolysis, hepatic dysfunction, and clinically important drug interactions.
These topics are addressed in Sections 5.1, 5.2, and 7.1-7.4.
Unsupported Statements
Yogurt itself is not known to reduce atorvastatin effectiveness.
The supplied label does not specifically address yogurt or establish that yogurt does not reduce atorvastatin effectiveness.
Yogurt does not have a well-established, clinically meaningful interaction with atorvastatin.
The supplied label does not evaluate yogurt or establish the absence of a clinically meaningful yogurt interaction.
There is no widely cited, consistent evidence that dairy calcium reliably decreases atorvastatin absorption enough to reduce its cholesterol-lowering effect.
This is an evidence-based conclusion not contained in the supplied prescribing information.
There is no widely cited, consistent evidence that yogurt protein reliably decreases atorvastatin absorption enough to reduce its cholesterol-lowering effect.
This is an evidence-based conclusion not contained in the supplied prescribing information.
Dark urine can occur with serious statin-related muscle toxicity and requires prompt evaluation.
The supplied label mentions myoglobinuria and acute renal failure in rhabdomyolysis but does not identify dark urine as a patient symptom or provide this specific instruction.
Contradictions
Important Omissions
The label states that atorvastatin may be taken as a single dose at any time of day, with or without food, and that LDL-C reduction is similar whether administered with or without food.
Importance:
Moderate
The label's grapefruit warning is particularly associated with excessive consumption, including more than 1.2 liters per day; the response does not provide this label-specific threshold.
Importance:
Moderate
The label instructs patients to promptly report unexplained muscle pain, tenderness, or weakness and states that therapy should be discontinued when myopathy is diagnosed or suspected.
Importance:
Moderate
The label recommends liver function testing before treatment, at 12 weeks after initiation and dose increases, and periodically thereafter.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response contains no material dosing error or direct contradiction and accurately highlights important interaction and muscle-safety information. Risk is limited because the yogurt-specific statements are framed cautiously, but they remain outside the supplied label and could be interpreted as definitive reassurance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
The response makes yogurt-, dairy-calcium-, and yogurt-protein-specific conclusions that are not supported by the supplied prescribing information and includes a dark-urine warning absent from the label.
Suggested Improvement
Limit the label-based answer to the statement that atorvastatin may be administered with or without food and that the label does not specifically address yogurt. Avoid presenting absence-of-evidence conclusions about yogurt, calcium, or protein as label-supported facts, and replace the dark-urine instruction with the label's explicit advice to promptly report unexplained muscle pain, tenderness, or weakness.